Cannabis bei Krebs: Mehr Chancen als Risiken?

Dr. Franjo Grotenhermen während der Laudatio für den IACM Special Award, verliehen an Prof. Mahmoud Elsohly beim Kongress der IACM 2015. Foto: Autor

Unser Gesprächspartner: Dr. med. Franjo Grotenhermen

• Literatur

• 1 Bar-Lev Schleider L, Mechoulam R, Lederman V. et al. Prospective analysis of safety and efficacy of medical cannabis in large unselected population of patients with cancer. Eur J Intern Med 2018; 49: 37-43
• 2 Franks LN, Ford BM, Fujiwara T. et al. The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects. Toxicol Appl Pharmacol 2018; 353: 31-42
• 3 Hashibe M, Morgenstern H, Cui Y. et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1829-1834
• 4 Hashibe M, Straif K, Tashkin DP. et al. Epidemiologic review of marijuana use and cancer risk. Alcohol 2005; 35: 265-275
• 5 Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2017; 2: 139-154
• 6 Musterdosierungsanleitungen für Dronabinol, Sativex, Nabilon und Cannabisblüten http://www.cannabis-med.org/german/dosierungsanleitung.rtf
• 7 Pressemitteilung von GW Pharmaceuticals vom 7. Februar 2017. Verfügbar online unter http://www.gwpharm.com/about-us/news/gw-pharmaceuticals-achieves-positive-results-phase-2-proof-concept-studyglioma